Molecular signatures of inherited and acquired sporadic late onset

Por um escritor misterioso
Last updated 17 maio 2024
Molecular signatures of inherited and acquired sporadic late onset
Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers. Unlike iNM, SLONM is amenable to therapy. The distinction between these disorders is therefore crucial when the diagnosis remains ambiguous after initial investigations. We sought to identify biomarkers facilitating this distinction and to investigate the pathophysiology of nemaline rod formation in these different disorders. Twenty-two muscle samples from patients affected by SLONM or iNM underwent quantitative histological analysis, laser capture microdissection for proteomic analysis of nemaline rod areas and rod-free areas, and transcriptomic analysis. In all iNM samples, nemaline rods were found in subsarcolemmal or central aggregates, whereas they were diffusely distributed within muscle fibers in most SLONM samples. In SLONM, muscle fibers harboring nemaline rods were smaller than those without rods. Necrotic fibers, increased endomysial connective tissue, and atrophic fibers filled with nemaline rods were more common in SLONM. Proteomic analysis detected differentially expressed proteins between nemaline rod areas and rod-free areas, as well as between SLONM and iNM. These differentially expressed proteins implicated immune, structural, metabolic, and cellular processes in disease pathophysiology. Notably, immunoglobulin overexpression with accumulation in nemaline rod areas was detected in SLONM. Transcriptomic analysis corroborated proteomic findings and further revealed substantial gene expression differences between SLONM and iNM. Overall, we identified unique pathological and molecular signatures associated with SLONM and iNM, suggesting distinct underlying pathophysiological mechanisms. These findings represent a step towards enhanced diagnostic tools and towards development of treatments for SLONM.
Molecular signatures of inherited and acquired sporadic late onset
Human SOX17 Antibody AF1924: R&D Systems
Molecular signatures of inherited and acquired sporadic late onset
Proteomics of brain, CSF, and plasma identifies molecular
Molecular signatures of inherited and acquired sporadic late onset
Genetic predisposition to gastrointestinal polyposis: syndromes
Molecular signatures of inherited and acquired sporadic late onset
Artificial Intelligence in Molecular Medicine
Molecular signatures of inherited and acquired sporadic late onset
Molecular mechanisms underlying totipotency
Molecular signatures of inherited and acquired sporadic late onset
Single-cell genomics in acquired bone marrow failure syndromes
Molecular signatures of inherited and acquired sporadic late onset
Single-Cell Epigenomics and Functional Fine-Mapping of
Molecular signatures of inherited and acquired sporadic late onset
Full article: To protect and modify double-stranded RNA – the
Molecular signatures of inherited and acquired sporadic late onset
Molecular principles of tissue invasion and metastasis
Molecular signatures of inherited and acquired sporadic late onset
Sporadic Late-Onset Nemaline Myopathy: Current Landscape
Molecular signatures of inherited and acquired sporadic late onset
From Molecules and Cells to Human Health - TIB AV-Portal
Molecular signatures of inherited and acquired sporadic late onset
The cytoskeleton in neurodegenerative diseases - Cairns - 2004
Molecular signatures of inherited and acquired sporadic late onset
The genetic basis of idiopathic pulmonary fibrosis

© 2014-2024 ambarfurniture.com. All rights reserved.